Cargando…

Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis

BACKGROUND: Although numerous studies confirmed the marked efficacy of chimeric antigen receptor T cells (CAR-T cells) in many hematologic malignancies, severe cardiovascular toxicities remain to be a major obstacle when incorporating this technology. Furthermore, previous individual investigations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Li-Rong, Li, Ya-Jia, Zhang, Zheng, Wang, Ping, Zhou, Tao, Qian, Kai, Fan, Yu-Xin, Guo, Yu, He, Gong-Hao, Shen, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682079/ https://www.ncbi.nlm.nih.gov/pubmed/36439485 http://dx.doi.org/10.3389/fonc.2022.924208

Ejemplares similares

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy
por: Wang, Yang, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome
por: He, Jinping, et al.
Publicado: (2022)

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis
por: Jang, Jong Keon, et al.
Publicado: (2022)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
por: Polgárová, Kamila, et al.
Publicado: (2022)

CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
por: Ye, Mingyu, et al.
Publicado: (2022)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy
por: Lipe, Demis N., et al.
Publicado: (2023)

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis
por: Grigor, Emma J M, et al.
Publicado: (2017)

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms
por: Thokala, Radhika, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells
por: Phanthaphol, Nattaporn, et al.
Publicado: (2021)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Cardiovascular disease and chimeric antigen receptor cellular therapy
por: Rao, Anjali, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study
por: Qi, Kunming, et al.
Publicado: (2021)

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
por: Jin, Ke-Tao, et al.
Publicado: (2021)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series
por: Dhaliwal, Armaan, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
por: Xiao, Bu-Fan, et al.
Publicado: (2021)

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)

Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy
por: Guan, Yuqi, et al.
Publicado: (2021)

Case report: Deep molecular remissions post two separate CD19-targeted chimeric antigen receptor T-cell therapies do not prevent disease from relapsing in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Tang, Yu, et al.
Publicado: (2023)

Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey
por: Ghafoor, Saad, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective
por: Marzal-Alfaro, María Belen, et al.
Publicado: (2021)

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
por: Fan, Mingxue, et al.
Publicado: (2017)

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019)

Cardiovascular Risk Profile of Chimeric Antigen Receptor T-cell Therapy
por: Ahmed, Talha
Publicado: (2020)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
por: Cao, Yaqing, et al.
Publicado: (2019)

Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
por: Yan, Nan, et al.
Publicado: (2021)

Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
por: Miyao, Kotaro, et al.
Publicado: (2023)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

Prognostic Value of Radiomic Features of (18)F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells
por: Zhou, Yeye, et al.
Publicado: (2022)

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients
por: Yu, Lihua, et al.
Publicado: (2021)

Anti-CD19 chimeric antigen receptor T-cell followed by interferon−α therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report
por: Ni, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_msnvfet4kesadubu730ml1hubj